# Charles River Laboratories International, Inc. (CRL)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $9.07B  
**Price:** $182.98 (-1.78%)

> Charles River Laboratories International, Inc. is a leading provider of essential products and services that support pharmaceutical, biotechnology, and medical device companies in drug discovery, development, and manufacturing. It operates through three core segments: Research Models and Services, which supplies specialized animal models, insourcing solutions, and accelerator and development labs for preclinical research; Discovery and Safety Assessment, delivering regulatory-required safety testing for new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices; and Manufacturing Solutions, offering microbial solutions for in vitro testing and biologics solutions including testing services and avian vaccines. These offerings enable clients to advance therapies from early discovery through safety validation and production support, playing a critical role in the preclinical and clinical stages of the life sciences industry. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories International, Inc. serves a global market with a focus on high-quality, compliant research and testing services.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $4.02B | — | $25M | -$144M | — |
| 2024 | $4.05B | — | $227M | $22M | — |
| 2023 | $4.13B | — | $617M | $475M | — |
| 2022 | $3.98B | — | $651M | $486M | — |
| 2021 | $3.54B | — | $590M | $391M | — |
| 2020 | $2.92B | — | $433M | $364M | — |
| 2019 | $2.62B | — | $351M | $252M | — |
| 2018 | $2.27B | — | $331M | $226M | — |
| 2017 | $1.86B | $1.57B | $288M | $123M | — |
| 2016 | $1.68B | $1.40B | $238M | $155M | — |
| 2015 | $1.36B | $1.10B | $206M | $149M | — |
| 2014 | $1.30B | $1.03B | $178M | $127M | — |
| 2013 | $1.17B | $893M | $151M | $103M | — |
| 2012 | $1.13B | $872M | $166M | — | — |
| 2011 | $1.14B | $875M | $174M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $7.14B | $3.92B | $3.16B | $214M | — |
| 2024 | $7.53B | $4.02B | $3.46B | $195M | — |
| 2023 | $8.20B | $4.54B | $3.60B | $277M | — |
| 2022 | $7.60B | $4.58B | $2.98B | $234M | — |
| 2021 | $7.02B | $4.43B | $2.53B | $241M | — |
| 2020 | $5.49B | $3.35B | $2.11B | $228M | — |
| 2019 | $4.69B | $3.03B | $1.63B | $238M | — |
| 2018 | $3.86B | $2.52B | $1.32B | $195M | $1.61B |
| 2017 | $2.93B | $1.87B | $1.05B | $164M | $1.09B |
| 2016 | $2.71B | $1.86B | $837M | $118M | $1.18B |
| 2015 | $2.07B | $1.30B | $733M | $118M | $814M |
| 2014 | $1.87B | $1.17B | $672M | $160M | $717M |
| 2013 | $1.63B | $968M | $641M | $156M | $663M |
| 2012 | $1.59B | $983M | $601M | $110M | $666M |
| 2011 | $1.56B | $1.03B | $526M | $69M | $718M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $738M | — | — |
| 2024 | $735M | — | — |
| 2023 | $684M | — | — |
| 2022 | $620M | — | — |
| 2021 | $761M | — | — |
| 2020 | $547M | — | — |
| 2019 | $481M | — | — |
| 2018 | $441M | — | — |
| 2017 | $318M | — | — |
| 2016 | $317M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/CRL)